Early Multicentre Real-World Outcomes of AnyraTM, a Novel Aflibercept Biosimilar, in Treatment-Naïve Retinal Diseases

INTRODUCTION: (Zydus Lifesciences Ltd., Ahmedabad, India), a novel aflibercept biosimilar (Afl-Bs), in treatment-naïve eyes with neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DME), retinal vein occlusion (RVO) or myopic macular neovascularization (MNV). METHODS: This multicentre retrospective observational study included 162 consecutive treatment-naïve eyes from 162 patients treated with a single intravitreal injection of Afl-Bs at five tertiary retina centres in India between April 2026 and May 2026. The cohort comprised 82 eyes with nAMD, 40 eyes with DME, 36 eyes with RVO and 4 eyes with myopic MNV. Best-corrected visual acuity (BCVA), converted to logarithm of the minimum angle of resolution (logMAR), central macular thickness (CMT), intraretinal fluid (IRF), subretinal fluid (SRF) and complete retinal drying were evaluated at baseline and 1 month. Paired t-tests and McNemar tests were used, as appropriate. RESULTS: Mean BCVA improved from 0.77 ± 0.40 logMAR at baseline to 0.55 ± 0.39 logMAR at 1 month (mean difference, -0.22 ± 0.26 logMAR; P < 0.001). Mean CMT decreased from 480.67 ± 207.8 µm to 309.13 ± 163.4 µm (mean difference, -71.54 ± 170.8 µm; P < 0.001). IRF was present in 120 eyes (74.1%) at baseline and 40 eyes (24.7%) at 1 month (P < 0.001); SRF decreased from 82 eyes (50.6%) to 33 eyes (20.4%) (P < 0.001). Complete retinal drying was observed in 96 eyes (59.3%) at 1 month. Significant improvements in BCVA and CMT were observed across nAMD, DME and RVO subgroups. No ocular or systemic adverse events were observed during follow-up. CONCLUSIONS: Early multicentre real-world experience suggests that Afl-Bs provides favourable short-term functional and anatomical outcomes across common retinal diseases, with no unexpected adverse events documented during the study period. Larger prospective comparative studies with longer follow-up are warranted to further evaluate its clinical effectiveness and safety.

Authors

Publication Details

Journal
Ophthalmology and Therapy
Published
2026-11-18
DOI
https://doi.org/10.1007/s40123-026-01538-3
Primary Topic
Retinal Diseases and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Early Multicentre Real-World Outcomes of AnyraTM, a Novel Aflibercept Biosimilar, in Treatment-Naïve Retinal Diseases

Somnath Chakraborty, Sanghamitra Kanungo, Aditya A. Sudhalkar, Jay Umed Sheth et al.
7 links
Ophthalmology and Therapy
Retinal Diseases and Treatments
article

Early Multicentre Real-World Outcomes of AnyraTM, a Novel Aflibercept Biosimilar, in Treatment-Naïve Retinal Diseases

Somnath Chakraborty, Sanghamitra Kanungo, Aditya A. Sudhalkar, Jay Umed Sheth, Shilpi Harshal Narnaware, Subijay Sinha
article en

Abstract

INTRODUCTION: (Zydus Lifesciences Ltd., Ahmedabad, India), a novel aflibercept biosimilar (Afl-Bs), in treatment-naïve eyes with neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DME), retinal vein occlusion (RVO) or myopic macular neovascularization (MNV). METHODS: This multicentre retrospective observational study included 162 consecutive treatment-naïve eyes from 162 patients treated with a single intravitreal injection of Afl-Bs at five tertiary retina centres in India between April 2026 and May 2026. The cohort comprised 82 eyes with nAMD, 40 eyes with DME, 36 eyes with RVO and 4 eyes with myopic MNV. Best-corrected visual acuity (BCVA), converted to logarithm of the minimum angle of resolution (logMAR), central macular thickness (CMT), intraretinal fluid (IRF), subretinal fluid (SRF) and complete retinal drying were evaluated at baseline and 1 month. Paired t-tests and McNemar tests were used, as appropriate. RESULTS: Mean BCVA improved from 0.77 ± 0.40 logMAR at baseline to 0.55 ± 0.39 logMAR at 1 month (mean difference, -0.22 ± 0.26 logMAR; P < 0.001). Mean CMT decreased from 480.67 ± 207.8 µm to 309.13 ± 163.4 µm (mean difference, -71.54 ± 170.8 µm; P < 0.001). IRF was present in 120 eyes (74.1%) at baseline and 40 eyes (24.7%) at 1 month (P < 0.001); SRF decreased from 82 eyes (50.6%) to 33 eyes (20.4%) (P < 0.001). Complete retinal drying was observed in 96 eyes (59.3%) at 1 month. Significant improvements in BCVA and CMT were observed across nAMD, DME and RVO subgroups. No ocular or systemic adverse events were observed during follow-up. CONCLUSIONS: Early multicentre real-world experience suggests that Afl-Bs provides favourable short-term functional and anatomical outcomes across common retinal diseases, with no unexpected adverse events documented during the study period. Larger prospective comparative studies with longer follow-up are warranted to further evaluate its clinical effectiveness and safety.

Ophthalmology and Therapy
Good health and well-being
Retinal Diseases and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon